Dyne Therapeutics maintains a strong $1.1B cash position, funding operations into mid-2028 despite heavy R&D and operating ...

New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history -- Data expand ...

Dyne Therapeutics is plotting an approval application for z-rostudirsen in the back half of 2026—a push that will only be bolstered by the departure of controversial CBER chief Vinay Prasad, according ...

HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 -- 48-week trial will enroll approximately 150 ...

Shares of Dyne Therapeutics gained after the company shared positive data from a continuing trial of a potential Duchenne muscular dystrophy treatment. The stock rose 14%, to $16.93, midday Monday.

Dyne Therapeutics has initiated the Phase III HARMONIA trial to evaluate the efficacy, safety, and tolerability of zeleciment basivarsen (z-basivarsen, also called DYNE-101) in individuals diagnosed ...

Breaking stock news is now free. Create your account to stay informed—and explore the insights behind every move. Dyne Therapeutics, Inc. ( DYN) TD Cowen 46th Annual Health Care Conference March 4, ...

This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach.

Dyne Therapeutics (DYN) is back in focus after Q4 2025 results showed a loss per share that came in ahead of expectations, alongside continued net losses and detailed progress in its late stage ...

Dyne Therapeutics, Inc. has announced a $275 million non-dilutive senior secured term loan facility with Hercules Capital, which includes an upfront funding of $100 million and the potential for an ...

Austin-based Saturn V Capital Management added 1.2 million shares of Dyne Therapeutics during the third quarter. According to a SEC filing for the period ended September 30, Saturn V Capital ...

Dyne Therapeutics (NASDAQ: DYN) was hardly having a bad case of the Mondays. Shares of the clinical-stage biotech were racing more than 9% higher in mid-session action, as the company delivered rather ...